Cardima Revelation Tx Receives Second Rejection Letter, May Need New Data
This article was originally published in The Gray Sheet
Executive Summary
Cardima may have to collect additional data on its Revelation Tx cardiac ablation catheter to earn FDA approval for an atrial fibrillation indication, the company acknowledged June 2
You may also be interested in...
FDA Dispute Panel Rebuffs Cardima’s Catheter A-Fib Claims
An FDA dispute resolution body all but halted Cardima's chances to turn around the fortunes of its Revelation Tx microcatheter NavAblator ablation system April 19, voting 5-0 not to recommend approval of the product
FDA Dispute Panel Rebuffs Cardima’s Catheter A-Fib Claims
An FDA dispute resolution body all but halted Cardima's chances to turn around the fortunes of its Revelation Tx microcatheter NavAblator ablation system April 19, voting 5-0 not to recommend approval of the product
St. Jude Augments AF Division With $47 Mil. Irvine Biomedical Purchase
St. Jude will evaluate whether to pursue an atrial fibrillation indication for Irvine Biomedical, Inc.'s Therapy, Dual 8 and Cooled-Tip ablation catheters